FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890892325> ?p ?o ?g. }

• W2890892325 abstract "Objectives: The purpose of this study was to investigate the impact of neoadjuvant chemotherapy (NAC) on perioperative morbidity and on oncological outcomes according to the type of chemotherapy regimen administered to patients with muscle-invasive bladder cancer (MIBC) who subsequently underwent radical cystectomy (RC). Methods: Data were collected retrospectively on 40 patients with bladder urothelial carcinoma who had at least two cycles of NAC, followed by RC, from 2011 to 2015 at our institution. The outcomes evaluated were NAC toxicity, perioperative complications, cancer-specific, and overall survival. Results: Among these cases, 23 patients (57.5%) received methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), 4 patients (10%) received gemcitabine and cisplatin (GC), and 13 patients (32.5%) received other regimes. The early and late postoperative complication rates were 35% and 12.5%. Regarding toxicity, 85% of patients had at least one side effect of NAC, but only 21.7% discontinued therapy in the MVAC group. The pathological complete response (pCR) rates for cisplatin-based regimens (MVAC and GC) and other regimens were 44.4 and 15.4%, respectively, (p = 0.09). The pathological partial response (pPR) rates for cisplatin-based regimens and other regimens were 66.7 and 15.4%, respectively, (p = 0.002). Patients treated with a cisplatin-based chemotherapy regimen had longer overall survival than those treated with other regimen (median 38.1 vs. 18.4 months, p = 0.01). Conclusions: NAC administration was not associated with high toxicity or surgical morbidity. The pathological response rates and survival outcomes in the cisplatin-based regimens were higher than with those with non-cisplatin-based regimens. These data support the use, in patients elective to a neoadjuvant setting prior to RC for MBIC, of a cisplatin-based regimen." @default.
• W2890892325 created "2018-09-27" @default.
• W2890892325 creator A5016735311 @default.
• W2890892325 creator A5020529503 @default.
• W2890892325 creator A5037810309 @default.
• W2890892325 creator A5039428493 @default.
• W2890892325 creator A5047485754 @default.
• W2890892325 creator A5050255590 @default.
• W2890892325 creator A5058559504 @default.
• W2890892325 date "2018-09-19" @default.
• W2890892325 modified "2023-10-18" @default.
• W2890892325 title "Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience" @default.
• W2890892325 cites W1527068138 @default.
• W2890892325 cites W1964037817 @default.
• W2890892325 cites W1972027031 @default.
• W2890892325 cites W1975918912 @default.
• W2890892325 cites W1988675200 @default.
• W2890892325 cites W2006111218 @default.
• W2890892325 cites W2006283915 @default.
• W2890892325 cites W2020945203 @default.
• W2890892325 cites W2026826756 @default.
• W2890892325 cites W2034679752 @default.
• W2890892325 cites W2064561270 @default.
• W2890892325 cites W2067084367 @default.
• W2890892325 cites W2073804272 @default.
• W2890892325 cites W2078191480 @default.
• W2890892325 cites W2103561213 @default.
• W2890892325 cites W2103725052 @default.
• W2890892325 cites W2117116444 @default.
• W2890892325 cites W2132219433 @default.
• W2890892325 cites W2146803580 @default.
• W2890892325 cites W2150447083 @default.
• W2890892325 cites W2166453367 @default.
• W2890892325 cites W2168846224 @default.
• W2890892325 cites W2462649057 @default.
• W2890892325 doi "https://doi.org/10.3389/fsurg.2018.00058" @default.
• W2890892325 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6156362" @default.
• W2890892325 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30283787" @default.
• W2890892325 hasPublicationYear "2018" @default.
• W2890892325 type Work @default.
• W2890892325 sameAs 2890892325 @default.
• W2890892325 citedByCount "16" @default.
• W2890892325 countsByYear W28908923252019 @default.
• W2890892325 countsByYear W28908923252020 @default.
• W2890892325 countsByYear W28908923252021 @default.
• W2890892325 countsByYear W28908923252022 @default.
• W2890892325 countsByYear W28908923252023 @default.
• W2890892325 crossrefType "journal-article" @default.
• W2890892325 hasAuthorship W2890892325A5016735311 @default.
• W2890892325 hasAuthorship W2890892325A5020529503 @default.
• W2890892325 hasAuthorship W2890892325A5037810309 @default.
• W2890892325 hasAuthorship W2890892325A5039428493 @default.
• W2890892325 hasAuthorship W2890892325A5047485754 @default.
• W2890892325 hasAuthorship W2890892325A5050255590 @default.
• W2890892325 hasAuthorship W2890892325A5058559504 @default.
• W2890892325 hasBestOaLocation W28908923251 @default.
• W2890892325 hasConcept C121608353 @default.
• W2890892325 hasConcept C126322002 @default.
• W2890892325 hasConcept C126894567 @default.
• W2890892325 hasConcept C141071460 @default.
• W2890892325 hasConcept C143998085 @default.
• W2890892325 hasConcept C2775910329 @default.
• W2890892325 hasConcept C2776694085 @default.
• W2890892325 hasConcept C2777132456 @default.
• W2890892325 hasConcept C2778239845 @default.
• W2890892325 hasConcept C2778292576 @default.
• W2890892325 hasConcept C2780258809 @default.
• W2890892325 hasConcept C2780352672 @default.
• W2890892325 hasConcept C2781413609 @default.
• W2890892325 hasConcept C31174226 @default.
• W2890892325 hasConcept C530470458 @default.
• W2890892325 hasConcept C71924100 @default.
• W2890892325 hasConceptScore W2890892325C121608353 @default.
• W2890892325 hasConceptScore W2890892325C126322002 @default.
• W2890892325 hasConceptScore W2890892325C126894567 @default.
• W2890892325 hasConceptScore W2890892325C141071460 @default.
• W2890892325 hasConceptScore W2890892325C143998085 @default.
• W2890892325 hasConceptScore W2890892325C2775910329 @default.
• W2890892325 hasConceptScore W2890892325C2776694085 @default.
• W2890892325 hasConceptScore W2890892325C2777132456 @default.
• W2890892325 hasConceptScore W2890892325C2778239845 @default.
• W2890892325 hasConceptScore W2890892325C2778292576 @default.
• W2890892325 hasConceptScore W2890892325C2780258809 @default.
• W2890892325 hasConceptScore W2890892325C2780352672 @default.
• W2890892325 hasConceptScore W2890892325C2781413609 @default.
• W2890892325 hasConceptScore W2890892325C31174226 @default.
• W2890892325 hasConceptScore W2890892325C530470458 @default.
• W2890892325 hasConceptScore W2890892325C71924100 @default.
• W2890892325 hasLocation W28908923251 @default.
• W2890892325 hasLocation W28908923252 @default.
• W2890892325 hasLocation W28908923253 @default.
• W2890892325 hasLocation W28908923254 @default.
• W2890892325 hasOpenAccess W2890892325 @default.
• W2890892325 hasPrimaryLocation W28908923251 @default.
• W2890892325 hasRelatedWork W2031349309 @default.
• W2890892325 hasRelatedWork W2122063636 @default.
• W2890892325 hasRelatedWork W2317145945 @default.
• W2890892325 hasRelatedWork W2349270370 @default.
• W2890892325 hasRelatedWork W2372296323 @default.
• W2890892325 hasRelatedWork W2603025253 @default.

• next